2Hariprasad SM,Mieler WF,Lin TK,et al.Voriconazole in the treatment of fungal eye infections:a review of current literature[J].Br J Ophthalmol,2008,92:871-878.
8Hariprasad SM,Mieler WF,Holz ER,et al.Determination of vitreous, aqueous,and plasma concentration of orally administered voriconazole in humans[J].Arch Ophthalmol,2004,122(1):42-47.
9Thiel MA,Zinkernagel AS,Burhenne J,et al.Voriconazole concentration in human aqueous humor and plasma during topical or combined topical and systemic administration for fungal keratitis[J].Antimicrob Agents Chemother,2007,51(1):239-244.
10William S,Nancy C,Demi D,et al.Topical Voriconazole as a Novel Treatment for Fungal Keratitis[J].Antimicrob Agents Chemother, 2006,50(1):262-268.
5LEWIS R E, WIEDERHOLD N P, KLESPER M E. In vitro pharmacodynamics of amphotericin B, itraconazole ,and voriconazole against aspergillus, fusarium,and scedosporium spp [J]. Antimicrob Agents and Chemother, 2005, 49(3): 945-951.
6LILY A J, FRANK J P, ALEKSANDR G L, et al. Voriconazole [J]. Clin Ther, 2003, 25(5): 1321-1381.
9National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; Approved Standards.NCCLS document M38-A(ISBN 1-56238-470-8). Wayne, Pennsylvania, USA 2002.
10Cuenca-Estrella M, Diaz-Garcia TM, Mellado E, et al. Comparative in vitro activity of voriconazole and itraconazole against fluconazole-susceptible and fluoconazole resistant clinical isolates of Candida species from Spain[J]. Eur J Clin Microbiol Infect Dis,1999,18:432-435.
